NRIX — Nurix Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $859.18m
- $309.50m
- $54.55m
- 44
- 14
- 41
- 24
Annual cashflow statement for Nurix Therapeutics, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43.2 | -117 | -180 | -144 | -194 |
| Depreciation | |||||
| Non-Cash Items | 4.57 | 17.6 | 28.8 | 28.8 | 23 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 36.4 | 9.11 | -19 | 20.1 | -18.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.08 | -84.4 | -160 | -81.4 | -173 |
| Capital Expenditures | -4.55 | -5.66 | -12.2 | -8.4 | -9.27 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -250 | -103 | 39.4 | 76.7 | -248 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -254 | -108 | 27.2 | 68.3 | -258 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 339 | 154 | 117 | 3.22 | 486 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 84.5 | -38.7 | -15.4 | -9.85 | 55.4 |